BUY 1 GET 1 50% OFF
no code needed

every product, sitewide — no code, applied automatically at checkout

side-by-side research comparison

GLP-3 RTA vs KPV

GLP-3 RTA and KPV come from different research areas and are studied in largely separate models — researchers usually compare them when scoping a broader protocol.

✓ both US-made · third-party tested · batch COA on every order

Last updated August 25, 2026

How do GLP-3 RTA and KPV differ?

GLP-3 RTA (Synthetic triple-agonist peptide) is catalogued under weight & metabolic research; KPV (Tripeptide alpha-MSH fragment) is catalogued under recovery & gut research. Verve lists 5 reported research applications for GLP-3 RTA and 5 for KPV. Both are made in the United States, screened by HPLC to a 99%+ purity standard, and shipped with a batch-level certificate of analysis.

GLP-3 RTA compared with KPV across compound class, research area, supply format, purity standard, documentation, catalog price and stock.
fieldGLP-3 RTAKPV
compound classSynthetic triple-agonist peptideTripeptide alpha-MSH fragment
research areaweight & metabolicrecovery & gut
reported research applications5 listed5 listed
supplied assingle compoundsingle compound
catalog sizes10mg · 20mg · 30mg10mg
purity standard99%+ by HPLC99%+ by HPLC
manufacturedUnited StatesUnited States
batch COApublished per lotpublished per lot
endotoxin-tested optionavailableavailable
co-formulated together innot co-formulatednot co-formulated
price from$142.99$93.49
availabilityin stockin stock

Prices and stock read live from the catalog. Both compounds are supplied strictly as reference materials for in-vitro laboratory research.

What is GLP-3 RTA and what is KPV?

GLP-3 RTA is classified as Synthetic triple-agonist peptide; KPV as Tripeptide alpha-MSH fragment. Both profiles below cover scientific identity only — what the molecule is and which laboratory models it appears in. Verve supplies both strictly as in-vitro reference materials, and neither profile describes human or veterinary use.

GLP-3 RTA

Synthetic triple-agonist peptide

GLP-3 RTA is a synthetic single-chain peptide engineered to act at three related class B G-protein-coupled receptors at once: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. Its backbone is derived from the incretin peptide family and carries a fatty-acid modification that extends plasma half-life in pre-clinical systems, making it a widely cited reference agonist in incretin-receptor research.

full GLP-3 RTA profile →

KPV

Tripeptide alpha-MSH fragment

KPV is a tripeptide composed of lysine, valine, and proline, corresponding to the C-terminal fragment (residues 11–13) of alpha-melanocyte-stimulating hormone (alpha-MSH). It is the smallest sequence retained from that parent peptide and is widely used as a compact reference compound in cellular signaling research, where its short chain length makes it convenient for controlled in-vitro work.

full KPV profile →

Which research models is each compound studied in?

GLP-3 RTA sits in weight & metabolic research and KPV in recovery & gut research, so their listed models largely do not intersect. The table lists 5 reported research applications for GLP-3 RTA and 5 for KPV. Rows are per compound, not equivalences.

Reported research applications listed for GLP-3 RTA and for KPV. Entries are listed per compound; a shared row is not a claim that the two applications are equivalent.
GLP-3 RTA — reported research applicationsKPV — reported research applications
GLP-1, GIP, and glucagon receptor agonism researchInflammatory-signaling research models (NF-κB pathway studies)
cAMP and class B GPCR signaling research modelsCytokine-expression research in cultured cells
Comparative single-, dual-, and triple-agonist pharmacology studiesMelanocortin-receptor and alpha-MSH fragment research
Metabolic-pathway and nutrient-handling research modelsEpithelial and mucosal-barrier research models
Peptide half-life, lipidation, and stability researchStructure–activity studies of short peptide fragments

Research contexts only. Both compounds are supplied for laboratory research use only, and no entry above describes an effect in humans or animals.

What sizes and prices does verve list for GLP-3 RTA and KPV?

GLP-3 RTA is listed from $142.99 and KPV from $93.49. The table below is every catalog size verve currently lists for the two compounds, at single-vial prices before the automatic multi-compound discount. Sizes describe the vial format supplied to the laboratory, nothing more.

Catalog sizes, single-vial prices and stock status for GLP-3 RTA and KPV.
compoundsize listedpriceavailability
GLP-3 RTA10mg$142.99in stock
GLP-3 RTA20mg$242.99in stock
GLP-3 RTA30mg$328.99in stock
KPV10mg$93.49in stock

Any 2 different compounds take 20% off, any 3 take 30% — applied automatically in the cart, no code. Orders placed Monday–Friday ship by 2pm CT, free over $100.

shop the compounds →

Frequently asked questions about GLP-3 RTA and KPV

What is GLP-3 RTA?

GLP-3 RTA is a synthetic peptide that acts as an agonist at three receptors — GLP-1, GIP, and glucagon. Verve supplies it as a research compound for laboratory use only, not for human or veterinary use.

What is GLP-3 RTA studied for in research?

In in-vitro and pre-clinical models it is used as a reference agonist in incretin-receptor pharmacology, cAMP signaling, and metabolic-pathway research. Verve makes no claims about use in humans or animals.

What is KPV?

KPV is a tripeptide (lysine-valine-proline) corresponding to the C-terminal fragment of alpha-MSH. Verve supplies it as a research compound for laboratory use only, not for human or veterinary use.

What is KPV studied for in research?

In in-vitro and pre-clinical models it is used as a reference compound in inflammatory-signaling, cytokine-expression, and melanocortin-pathway research. Verve makes no claims about use in humans or animals.

related comparisons

verve products are sold for laboratory research and development purposes only and are not intended for human or veterinary use of any kind. statements on this site have not been evaluated by the FDA.